


- (c) a sulfonylurea;
- (d) a biguanide; and
- (e) an alpha-glucosidase inhibitor.]



1C297. (Amended) A method as claimed in claim 1 including adding a pharmaceutical carrier to the therapeutically effective amount of the anti-diabetic agent [drug].

(Amended) A composition for the treatment of diabetes mellitus comprising:

- (a) a therapeutic amount of an insulin sensitizer; and
- (b) a therapeutic amount of an anti-diabetic agent. [a drug selected from the group consisting of: an orally ingestible insulin; an injectible insulin; a sulfonylurea; a biguanide; and an alpha-glucosidase inhibitor.]

Please add the following claims:

30. A method as claimed in claim 1, wherein the anti-diabetic agent is selected from the group consisting of:

- (a) an orally ingestible insulin;
- (b) an injectible insulin;
- (c) a sulfonylurea;
- (d) a biguanide; and
- (e) an alpha-glucosidase inhibitor.

~~31.~~ A composition as claimed in claim ~~8~~, wherein the anti-diabetic agent is selected from the group consisting of: an orally ingestible insulin; an injectible insulin; a sulfonylurea; a biguanide; and an alpha-glucosidase inhibitor.

82. A composition as claimed in claim 81, wherein the anti-diabetic agent is

73

1

insulin.

¹⁴33. A composition as claimed in claim ³32, wherein the insulin is injectible insulin.

²¹34. A method for the treatment of diabetes mellitus comprising administering to a person afflicted with diabetes mellitus a therapeutic amount of an insulin sensitizer with a therapeutic amount of an orally ingestible anti-diabetic agent, wherein

(1) the insulin sensitizer is selected from the group consisting of: BRL-49653, Pioglitazone HCL, Troglitazone, MC 555, ALRT 268, LGD 1069, Chromic Picolinate and V-411, and wherein

(2) the anti-diabetic agent is selected from the group consisting of: an orally ingestible insulin; an injectible insulin; a sulfonylurea; a biguanide; and an alpha-glucosidase inhibitor.

³Donald: ²²35. The method of claim ²¹34, wherein the insulin sensitizer is V-411.

²³36. The method of claim ²¹34, wherein the anti-diabetic agent is an orally ingestible anti-diabetic agent.

²⁴37. The method of claim ²²36, wherein the anti-diabetic agent is a sulfonylurea.

²⁴38. The method of claim ²²35 wherein the anti-diabetic agent is an orally ingestible insulin.